Correction to “Apratoxin S10, a Dual Inhibitor of Angiogenesis and

Correction Cite This: ACS Med. Chem. Lett. 2017, 8, 1342−1342

Correction to “Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors” Weijing Cai, Qi-Yin Chen, Long H. Dang, and Hendrik Luesch* ACS Med. Chem. Lett. 2017, 8 (10) 1007−1012. DOI: 10.1021/acsmedchemlett.7b00192

D

ue to a production error, Figures 4 and 5 were transposed during the final page preparation. They appear correctly with the appropriate caption below.

Figure 4. Activity of apratoxin S10 on VEGF-A and IL-6 secretion, 24 h. VEGF-A secretion from (a) A498, (b) Huh7, and (c) NCI-H727 cells detected using AlphaLISA Human VEGF-A Immunoassay Kit (PerkinElmer). IL-6 secretion from (d) A498 and (e) Huh7 cells detected using AlphaLISA Human IL-6 Immunoassay Kit (PerkinElmer). Error bars indicate mean ± SD of three replicates.

Figure 5. Immunoblot analysis of apratoxin S10-treated (a) A498, (b) NCI-H727, and (c) Huh7 cells, 24 h. Apratoxin S10 downregulated multiple RTKs.

Published: December 7, 2017 © 2017 American Chemical Society

1342

DOI: 10.1021/acsmedchemlett.7b00498 ACS Med. Chem. Lett. 2017, 8, 1342−1342